Crossmark Global Holdings, Inc. Collegium Pharmaceutical, Inc Transaction History

Crossmark Global Holdings, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$17.5 - $21.35 $371,000 - $452,620	-21,200 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$17.75 - $25.39 $376,300 - $538,268	21,200 New	21,200 $418,000
Q3 2021 Oct 13, 2021	SELL	$17.75 - $25.39 $376,300 - $538,268	-21,200 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$21.74 - $25.28 $2,391 - $2,780	110 Added 0.52%	21,200 $501,000
Q1 2021 Apr 15, 2021	BUY	$19.25 - $26.1 $405,982 - $550,449	21,090 New	21,090 $500,000

249

36.2M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.11B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.